Over the last 7 days, the United States market has experienced a 1.9% drop, yet it remains up by an impressive 30% over the past year with earnings anticipated to grow by 15% annually in the coming years. In this context of robust long-term growth potential despite short-term fluctuations, identifying high-growth tech stocks that align well with these market dynamics can be crucial for investors seeking opportunities in November 2024.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 244 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Advanced Energy Industries

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Advanced Energy Industries, Inc. offers precision power conversion, measurement, and control solutions globally and has a market capitalization of $4.13 billion.

Operations: The company generates revenue primarily from its Power Electronics Conversion Products segment, amounting to $1.47 billion.

Amidst a challenging fiscal landscape, Advanced Energy Industries (AEIS) has demonstrated resilience with plans to enhance its market position through strategic acquisitions and internal innovations. Recently, AEIS announced a quarterly dividend of $0.10 per share while actively seeking acquisitions to bolster its product lineup and market reach. Despite a net loss of $14.91 million in Q3 2024, the company is optimistic about future growth, projecting revenue increases up to 9.5% annually—surpassing the US market average of 8.9%. Furthermore, AEIS is committed to expanding its R&D capabilities as evidenced by the opening of a new design center in Wilmington, MA, aimed at accelerating technology development for key sectors like semiconductors and medical applications. This focus on innovation and expansion underpins AEIS's strategy to not only recover but also thrive by potentially increasing gross margins above 40%, aligning with an anticipated earnings growth rate of 69.2% per year.

• Get an in-depth perspective on Advanced Energy Industries' performance by reading our health report here.

• Examine Advanced Energy Industries' past performance report to understand how it has performed in the past.

Cellebrite DI

Simply Wall St Growth Rating: ★★★★★☆

Overview: Cellebrite DI Ltd. provides digital intelligence solutions for legally sanctioned investigations across various regions including Europe, the Middle East, Africa, the Americas, and the Asia-Pacific, with a market cap of $4.04 billion.

Operations: Cellebrite DI Ltd. generates revenue primarily from its Internet Software & Services segment, amounting to $346.76 million. The company focuses on developing digital intelligence solutions tailored for legally sanctioned investigations across multiple global regions.

Cellebrite DI Ltd. is navigating a transformative phase with a sharp focus on enhancing its technological capabilities and market reach. Despite currently being unprofitable, the company's revenue is expected to grow at 13.9% annually, outpacing the US market average of 8.9%. This growth trajectory is underpinned by substantial R&D investments, which have been pivotal in driving innovation and maintaining competitive edge in the digital intelligence sector. Recently, Cellebrite revised its full-year revenue outlook upwards to between $390 million and $398 million, reflecting confidence in its operational strategy and product offerings. Furthermore, with an anticipated profitability within three years and a forecasted return on equity of 101.9%, Cellebrite demonstrates potential for robust financial health ahead.

• Take a closer look at Cellebrite DI's potential here in our health report.

• Explore historical data to track Cellebrite DI's performance over time in our Past section.

SpringWorks Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patients with rare diseases and cancer, with a market cap of $2.27 billion.

Operations: SpringWorks Therapeutics focuses on developing and commercializing treatments for rare diseases and cancer, targeting underserved patient populations. The company operates as a commercial-stage biopharmaceutical entity with a market cap of approximately $2.27 billion.

SpringWorks Therapeutics is making notable strides in the biotech sector, particularly with its recent FDA acceptance of the New Drug Application for mirdametinib, which shows promise as a pioneering treatment for neurofibromatosis type 1. This development could position SpringWorks at the forefront of NF1 therapy, especially given its potential market exclusivity and therapeutic superiority highlighted by Fast Track and Orphan Drug designations. Financially, while still navigating through net losses—with a significant reduction to $39.92 million in Q2 from $77.93 million year-over-year—the company's revenue trajectory is impressive, recording a 43.5% annual growth rate that outpaces the broader US market's 8.9%. This robust growth is underpinned by R&D investments aimed at enriching its pipeline and enhancing drug efficacy, positioning SpringWorks for potential profitability within three years amidst a landscape where effective NF1 treatments are scarce.

• Navigate through the intricacies of SpringWorks Therapeutics with our comprehensive health report here.

• Review our historical performance report to gain insights into SpringWorks Therapeutics''s past performance.

Next Steps

• Dive into all 244 of the US High Growth Tech and AI Stocks we have identified here.
• Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGS:AEIS NasdaqGS:CLBT and NasdaqGS:SWTX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com